Phospho-BRCA1 (S1423) Antibody

1. We conclude that BRCA1 and BRCA2 could be used as clinicopathological biomarkers to evaluate the prognosis of digestive system cancers. PMID: 29126833
2. RAP80-BRCA1 complex foci formation is regulated by USP13.BRCA1 role in the DNA damage response. PMID: 28569838
3. RANK/RANKL were identified as crucial regulators for BRCA1 mutation-driven breast cancer. Current prevention strategies for BRCA1 mutation carriers are associated with wide-ranging risks; therefore, the search for alternative, non-invasive strategies is of paramount importance PMID: 29241686
4. Neither the patients tested nor the control subjects showed germline hypermethylation of the BRCA1 and BRCA2 promoter regions analyzed PMID: 29404838
5. Male carrying BRCA mutations have significantly lower QMAX than healthy men. BRCA1 patients have on average larger prostate glands and higher PSA than BRCA2 patients. PMID: 28577930
6. Results provide evidence that BRCA1 undergoes intronic premature polyadenylation (pPA) following large internal exons, and that N(6)-methyladenosine levels in this exon are reduced in pPA-activated breast cancer cells. PMID: 29362392
7. The combination of immunohistochemical expression of BRCA1, ER, PR, and HER-2/neu and clinicopathological details may be helpful in predicting the individuals more likely to carry BRCA1 mutations and thus selecting the candidate and family members for genetic screening for BRCA1 mutations. PMID: 29567881
8. methylation of BRCA1 was found to be significantly associated with tumor grade PMID: 30049201
9. The IRIS-driven metastatic mechanism results from IRIS-dependent suppression of phosphatase and tensin homolog (PTEN) transcription, which in turn perturbs the PI3K/AKT/GSK-3beta pathway leading to prolyl hydroxylase-independent HIF-1alpha stabilization and activation in a normoxic environment. PMID: 30254159
10. Both BRCA1 and BRCA2 mutations are associated with an increased risk for Prostate cancer(PC). BRCA2 in particular confers a more aggressive PC phenotype with a higher probability of locally advanced and metastatic disease, and should be considered a prognostic marker associated with poorer survival PMID: 29242595
11. Among BRCA mutation( BRCA1 or BRCA2) carriers, the mortality benefit of preventive mastectomy at age 25 is substantial, but the expected benefit declines rapidly with increasing age at surgery. PMID: 28914396
12. Significant increase in frequencies ofTP53 (rs1042522 G/C), BRCA1 (rs71361504 -/GTT, rs3092986T/C) genotypes and alleles in polycystic ovary patients compared to controls. PMID: 29860059
13. BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions. PMID: 30036938
14. this family depicts the intertwining cancer spectrum of with hereditary breast and ovarian cancer (HBOC) and familial pancreatic cancer (FPC) in BRCA1 families and raises awareness for the significance of considering pancreatic (head) adenocarcinoma (PAC)as differential phenotypic representation of the HBOC tumor spectrum. (Fig. 1a) and one pancreatic (head) adenocarcinoma (PAC) PMID: 28900739
15. High BRCA1 promoter methylation is linked to tumor grade and lymph node metastasis in breast cancer. PMID: 29970689
16. The present study demonstrates a clear protective effect of early first pregnancy on breast cancer risk in both BRCA1 and BRCA2 mutation carriers. PMID: 29116468
17. BRCA1 deficiency was recurrent in early-onset triple-negative breast cancer in Brazilian patients and associated with improved survival PMID: 29116469
18. Overall, 5152 oncogenetic tests were reviewed in the present study, of which 4452 had no a priori known familial mutation. The majority of participants (68.6%) were genotyped because of personal history of cancer; 20.6% were tested because of family history of cancer, and details for the remaining 10.7% were missing. Overall, 256/4452 (5.8%) carriers were detected, 141 BRCA1 and 115 BRCA2 mutation carriers. PMID: 29086229
19. CLDN3 expression and negative EGFR expression are associated with BRCA1 mutations in triple-negative breast cancers. PMID: 30142017
20. The present study aimed to clarify the clinicopathological features, including the level of p53 protein expression and BRCA mutations, of primary fallopian tube cancer (PFTC) in Japanese women. PMID: 29982601
21. s found that BRCA1/2 germline mutations in China exhibit distinct characteristics compared to those in Western populations. PMID: 29681614
22. analysis confirmed association between BRCA1 promoter methylation and breast cancer in Asia PMID: 29693332
23. A novel electrochemical DNA (E-DNA) biosensing strategy was designed and used for the detection of breast cancer susceptibility gene (BRCA-1). PMID: 29698810
24. Data suggest that targeting of breast cancer 1, early onset protein (BRCA1)-ribonucleotide reductase regulatory subunit M2 (RRM2) axis may represent a paradigm for therapeutic intervention in glioblastoma (GBM). PMID: 27845331
25. We show a strong association between Triple Negative Breast Cancer and mutations in BRCA1/2 genes and the poor outcome of these patients. The survival curve analysis showed that the presence of AKT1, TP53, KDR, KIT, BRCA1 and BRCA2 mutations is correlated with a poor prognosis. PMID: 29202330
26. Germline Mutation in the BRCA1 3'UTR Variant is associated with Breast Cancer. PMID: 29582646
27. Homozygous loss of function BRCA1 variant causes a Fanconi-anemia-like phenotype. PMID: 29133208
28. In summary, Nestin was strongly associated with germline BRCA1 related breast cancer, a basal-like phenotype, reduced survival, and stemness characteristics. PMID: 28439082
29. Homozygous nonsense mutations in the tumor suppressor gene BRCA1 is associated with breast and ovarian cancer. PMID: 29712865
30. Low BRCA1 expression is associated with radioresistance of glioma. PMID: 29286157
31. BRCA1 germ line mutation is associated with unilateral triple-negative breast cancer. PMID: 29514593
32. BRCA1 germ line mutation is associated with ovarian cancer. PMID: 29506471
33. High Promoter Methylation of BRCA1 gene is associated with Breast Cancer. PMID: 29480000
34. Ewing sarcoma cells display alterations in regulation of damage-induced transcription, accumulation of R-loops and increased replication stress; homologous recombination is impaired in Ewing sarcoma owing to an enriched interaction between BRCA1 and the elongating transcription machinery; also, a role is found for EWSR1 in the transcriptional response to damage, suppressing R-loops and promoting homologous recombination PMID: 29513652
35. Data indicate that BRCA1/2 mutations are not uncommon among selected Jordanian females with breast cancer. PMID: 29409476
36. Data show that male BRCA1/2 mutation carriers with breast and prostate cancer indicated a favorable 5-year survival. PMID: 29433453
37. findings provided the evidence that gBRCA1/2 mutation was not associated with survival in Chinese EOC patients, which possibly attributed to more than 37% of the patients without gross residual disease. Survival benefit of gBRCA1/2 mutation was prominent in ovarian cancer patients with gross residual disease. PMID: 29975922
38. BRCA1 SNP rs1799950 is associated with Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas. PMID: 29298688
39. The results of Ion PGM with OTG-snpcaller, a pipeline based on Torrent mapping alignment program and Genome Analysis Toolkit, from 75 clinical samples and 14 reference DNA samples were compared with Sanger sequencing for BRCA1/BRCA2. PMID: 28392550
40. Reduced BRCA1 expression was associated with ER and PR negative status resulting in Breast Carcinoma. PMID: 29286222
41. In this study, we used comprehensive multigene panels that included 35 known or suspected cancer susceptibility genes to examine BRCA1/2 mutation-negative Korean patients who had clinical features indicative of hereditary breast cancer PMID: 29338689
42. Pre-menopausal BRCA1/2 mutation carriers aged 30 to 47years chose screening, RRSO, or BS/DO. For those undergoing BS/DO, the delayed oophorectomy was recommended at age 40years for BRCA1 and age 45years for BRCA2 patients. PMID: 29735278
43. Based on a cumulative risk of 0.55% to age 35 for BRCA1 mutation carriers and of 0.56% to age 45 for BRCA2 mutation carriers, we recommend bilateral salpingo-oophorectomy before age 40, but by age 35, for women with a BRCA1 mutation and by age 45 for those with a BRCA2 mutation to maximize prevention and to minimize adverse effects. PMID: 29793803
44. We demonstrate that homologous recombination deficiency (HRD)mutation signatures may offer clinically relevant information independently of BRCA1/2 mutation status and hope this work will guide the development of clinical trials PMID: 29246904
45. Overall, 65/648 (10%) study participants were BRCA1/2 mutation carriers. PMID: 30061222
46. BRCA1*R1699Q confers an intermediate risk for breast cancer and ovarian cancer. PMID: 28490613
47. patient-derived xenografts capture the molecular and phenotypic heterogeneity of triple-negative breast cancer . Here we show that PARP inhibition can have activity beyond germline BRCA1/2 altered tumors, causing regression in a variety of molecular subtypes. These models represent an opportunity for the discovery of rational combinations with targeted therapies and predictive biomarkers PMID: 29093017
48. BRCA methylation is rare in breast and ovarian carcinomas of BRCA germline mutation carriers, although the frequency of BRCA promoter methylation may be underestimated. This could have major implications for clinical practice, including referral for genetic testing and BRCAness analysis for treatment decision-making. PMID: 29891109
49. Carboplatin and talazoparib showed efficacy in DNA damage mutation carriers, but hematologic toxicity was more pronounced in gBRCA(gBRCA1/2) carriers. Carboplatin is best combined with intermittent talazoparib dosing differentiated by germline and somatic DNA damage mutation carriers PMID: 28790114
50. Putative BRCA1/2 reversion mutations can be detected by cfDNA sequencing analysis in patients with ovarian and breast cancer. Our findings warrant further investigation of cfDNA sequencing to identify putative BRCA1/2 reversion mutations and to aid the selection of patients for PARP inhibition therapy PMID: 28765325

显示更多

收起更多

HGNC: 1100

OMIM: 113705

KEGG: hsa:672

STRING: 9606.ENSP00000418960

UniGene: Hs.194143